Current evidence suggests that blood eosinophil levels (Eos) are associated with chronic obstructive pulmonary disease (COPD) treatment response and natural history. This analysis investigated the relationship between Eos clinical characteristics in a representative cohort of US subjects spirometry-defined COPD.Cross-sectional data from National Health And Nutrition Examination Survey (NHANES 2007-2010) ≥ 40 years COPD (n = 948) were analyzed. Differences by level (≤ 2%, > 2%) compared using...

Despite recognition of asthma as a growing global issue and development guidelines, treatment practices vary between countries. Several studies have reported patients’ perspectives on control. This study presents physicians’ strategies for management. Physicians seeing ≥4 adult patients with per month in Australia, Canada, China, France, Germany, Japan were surveyed (N=1809; ≈300 country). A standardised questionnaire was developed this administered by telephone, online or face-to-face....

Observational studies using case-control designs have showed an increased risk of pneumonia associated with inhaled corticosteroid (ICS)-containing medications in patients chronic obstructive pulmonary disease (COPD). New-user observational cohort may minimize biases previous designs.To estimate the association between ICS and among new users relative to long-acting bronchodilator (LABD) monotherapy.Pneumonia events COPD ≥45 years old were compared (n = 11,555; ICS, ICS/long-acting...

To identify clusters of patients who may benefit from treatment with an inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) versus LABA alone, in terms exacerbation reduction, and to validate previously identified chronic obstructive pulmonary disease (COPD) (based on diuretic use reversibility). Post hoc supervised cluster analysis using a modified recursive partitioning algorithm two 1-year randomised, controlled trials fluticasone furoate (FF)/vilanterol (VI) VI the primary end...

Background: New hereditary angioedema (HAE) treatments have become available in recent years for the treatment of HAE due to C1-inhibitor (C1-INH) deficiency, including two subcutaneous (SC) options: a monoclonal antibody (lanadelumab) and plasma-derived C1-INH concentrate (SC-C1-INH). Limited real-world data on these therapies been reported. Objective: The objective was describe new users lanadelumab SC-C1-INH, demographics, healthcare resource utilization (HCRU), costs, patterns before...

Plain Language SummaryWhat is the study about?Hemophilia A a genetic bleeding disorder that causes for long periods because of lower than normal levels factor VIII (FVIII), protein important blood clotting. FVIII replacement therapy typical approach to manage bleeds, but new and improved therapies are becoming widely available. Prophylaxis with medication emicizumab gene valoctocogene roxaparvovec two such novel treatments approved use in adults severe hemophilia without inhibitors.Two...

The inclusion of an asthma/chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) population in the 2015 Global Initiative for Chronic Obstructive Lung Disease strategic documents has raised questions about profile these patients clinical practice, as they are mostly excluded from asthma and COPD trials. We estimated burden, co-morbidities, respiratory treatments with asthma/COPD overlap, utilizing Truven MarketScan commercial Medicare databases. Patients ≥1 or chronic...

Objective: To describe patient characteristics, treatment patterns and healthcare utilization (HCU) of non-active users maintenance asthma medications in the United Kingdom.Methods: Retrospective, cohort analysis patients with asthma, aged ≥ 6 years who were therapy (no prescription for inhaled corticosteroids (ICS), combined ICS/long-acting beta agonists (ICS/LABA) or 'other' bronchodilatory therapies last 12 months) identified Clinical Practice Research Datalink (2012–2015) followed-up 2...

Abstract Background Haemophilia A (HA; Factor VIII deficiency) is a congenital X-linked bleeding disorder characterized by trauma-related or spontaneous events, most notably arising within the intraarticular space and resulting in chronic inflammation degeneration of affected joints. Endogenous clotting factor activity relative to normal levels determines severity HA symptoms, as mild (> 5–40%), moderate (1–5%), severe (< 1%). Within current environment rapid evolution management, we...

Background: Pneumonia poses a significant risk in patients with moderate to severe chronic obstructive pulmonary disease but data are limited on the phenotypes most susceptible pneumonia. Methods: Cluster analysis using data-driven recursive partitioning algorithm was employed baseline from two pooled one-year randomized exacerbation trials (n=3,255) of fluticasone furoate/vilanterol or vilanterol alone identify distinct patient groups at greatest pneumonia serious (hospitalization death)...

BACKGROUND: Standard of care for bleed prevention in patients with severe congenital hemophilia A is continuous prophylaxis factor VIII (FVIII), typically administered intravenously 2-3 times per week the home setting. Nonfactor and gene therapy are emerging novel strategies A, it important to compare their health economics that FVIII prophylaxis. Current data on resource utilization costs adult population limited, a structured approach analyze annual these using administrative claims has...

Asthma and allergic rhinitis (AR) frequently coexist, having both asthma AR is associated with uncontrolled a heavier disease burden. The Asia-Pacific Survey of Physicians on Allergic Rhinitis (ASPAIR) aimed to assess physicians' perceptions their management practices for patients coexistent disease.A total 1,204 general physicians pediatricians from six countries in Asia, who routinely treat patients, were interviewed in-person. questioned about attitudes beliefs asthma-AR, how they...

Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use ICS/LABAs by comparing treatment persistence adherence among patients asthma in the United Kingdom initiating fluticasone furoate/vilanterol (FF/VI) versus budesonide/formoterol (BUD/FM) or beclometasone dipropionate/formoterol (BDP/FM). A retrospective new-user active comparator database...

Abstract This observational claims-linked survey study assessed the prevalence of and risk factors for suboptimal asthma control healthcare utilization in adults with receiving fixed-dose combination (FDC) inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA). Commercially insured from Optum Research Database were invited to complete Asthma Control Test (ACT) Questionnaire-6 (ACQ-6). Among participants ( N = 428), 36.4% (ACT-assessed) 55.6% (ACQ-6-assessed) had inadequately controlled...

Aims To assess real-world use of emicizumab in adult people with hemophilia A (PwHA) without inhibitors including healthcare resource utilization (HCRU) and costs.Materials methods Adult, male PwHA initiating (index date) were identified using IBM MarketScan after 4 October 2016. Patients required to have continuous health insurance coverage for ≥180 days prior ≥90 index date emicizumab. followed until treatment gap, disenrollment, or end data. Results reported overall among a subgroup...

BACKGROUND: Standard of care for patients with severe hemophilia A (HA) is life-long prophylaxis factor VIII (FVIII) concentrate or other hemostatic agents. Published literature highlights a wide range treatment costs HA. OBJECTIVE: To estimate average annual health and resource utilization cross-section adult managed FVIII using recent data from large US commercial claims database. METHODS: Adult males 1 more claim HA diagnosis, continuous plan enrollment, 4 prescription dispenses during 12...

This study investigated burden of 'not well-controlled' asthma, overall and by Global Initiative for Asthma (GINA) Step, among treated asthma patients in Practice Fusion's research database. control (Asthma Control Test [ACT]) was stratified GINA Step; prevalence ratios were estimated using Poisson regression with robust variance controlled confounders. ACT scores ≤19 reflect not well-controlled; >19 'well-controlled' asthma. Of 15,579 patients, 30% had well-controlled at index date. The...

Abstract Introduction Head‐to‐head evaluation of valoctocogene roxaparvovec, the first gene therapy approved for haemophilia A, with emicizumab is not available. Therefore, phase 3 trial data were indirectly compared. Aim To compare bleeding rates in trials evaluating 6 × 10 13 vg/kg roxaparvovec (GENEr8‐1; NCT03370913), 1.5 mg/kg dosed every week (HAVEN 3; NCT02847637), and FVIII prophylaxis (270–902) participants severe A (FVIII ≤1 IU/dL). Methods Valoctocogene versus as used 270–902...

A prospective, non-interventional study (270-902) followed 294 adults with severe hemophilia (SHA) receiving prophylactic factor VIII (FVIII). From these participants, 112 rolled over into a single-arm, multicenter, phase 3 trial (GENEr8-1; NCT03370913) that evaluated efficacy and safety of valoctocogene roxaparvovec, gene therapy provides endogenous FVIII in individuals SHA. Participants from 270-902 who did not roll provide an opportunity for contemporaneous external control. Therefore,...

Background: In China, the prevalence of allergic rhinitis (AR) and asthma has increased in past decade. As these two diseases frequently coexist, Asia-Pacific Survey Physicians on Asthma Allergic Rhinitis (ASPAIR) study aimed to assess physicians’ beliefs treatment patterns coexistent asthma-AR across six Asian countries. This analysis presents results from China. Methods: The 200 hospital-based general physicians pediatricians were interviewed five cities questioned in-person about their...

Background Underdiagnosis and undertreatment of allergic rhinitis (AR) in patients with asthma can worsen treatment outcomes. There is limited evidence clinical practices for management coexistent AR-asthma Thailand. Methods A multicountry, cross-sectional study (Asia-pacific Survey Physicians on Asthma Rhinitis) to evaluate physician perceptions related overlap 6 Asian countries was conducted. For Thailand specifically, linkage questionnaires were developed translated Thailaland. General...

Abstract Hemophilia A is characterized by unpredictable spontaneous bleeds and chronic comorbidities. However, limited data exists at the national level into detailed management patterns related to patient clinical characteristics, representative real‐world dosing treatment frequency, costs. To assess characterize US severe hemophilia (SHA) population, including subgroups of patients, in terms demographic healthcare resource utilization received centers (HTCs), projected annual costs...